Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer (2023) Slamon DJ, Fasching PA, Hurvitz S, Chia S, Crown J, Martín M, Barrios CH, et al. Journal article Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison (2023) Rugo HSS, Harmer V, O'Shaughnessy J, Jhaveri K, Tolaney SMM, Cardoso F, Bardia A, et al. Journal article Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2− advanced breast cancer (2023) Jhaveri K, O’Shaughnessy J, Fasching PA Journal article Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. (2023) Slamon DJ, Fasching P, Hurvitz S Journal article, Erratum Identification of an endogenous retroviral signature to predict anti-PD1 response in advanced clear cell renal cell carcinoma: an integrated analysis of three clinical trials (2022) Zhou J, Zeng Y, Wang H, Jin SH, Wang YJ, He S, Frey B, et al. Journal article Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup (2020) Emons J, Fasching P, Wunderle M, Heindl F, Rieger J, Horn F, Pelzer G, et al. Journal article NF-κB activation triggers NK-cell stimulation by monocyte-derived dendritic cells. (2019) Bosch NC, Voll RE, Voskens CJ, Gross S, Seliger B, Schuler G, Schaft N, Dörrie J Journal article Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination (2017) Gerer KF, Erdmann M, Hadrup SR, Lyngaa R, Martin LM, Voll RE, Schuler-Thurner B, et al. Journal article